Laia Rubio Ortega

Institutions of which they are part

Research technician
Gene Therapy at Nervous System

Vall Hebron Institut de Recerca

Laia Rubio Ortega

Institutions of which they are part

Research technician
Gene Therapy at Nervous System

Vall Hebron Institut de Recerca

Projects

ESTUDIO Y DESARROLLO DE LA PRIMERA PLATAFORMA TECNOLÓGICA DE ENSAYOS PARA VIRUS ADENOASOCIADOS EN TERÁPIA GÉNICA

IP: Miguel Chillon Rodriguez
Collaborators: Susana Miravet Delgado, Laia Rubio Ortega, Marina Tarrés Mercader, ESTUDIO Y DESARROLLO DE LA PRIMERA PLATAFORMA TECNOLÓGICA DE ENSAYOS PARA VIRUS ADENOASOCIADOS EN TERÁPIA GÉNICA
Funding agency: Instituto de Salud Carlos III
Funding: 296571
Reference: PMPTA22/00048
Duration: 01/01/2023 - 30/06/2025

Related news

FDA grants orphan drug designation to a gene therapy for ALS

The treatment, licensed to Klotho Neurosciences, is based on a technology developed at the Universitat Autònoma de Barcelona (UAB) with the participation of VHIR.

European Partnership Opens a New Era in Rare Disease Research

The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

VHIR leads a gene therapy study to stop the progression of neurodegenerative diseases

This gene therapy protects mice against cognitive deficits associated with aging, improves motor function, and delays the onset of diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.